患者对系统性狼治疗的偏好 - - 一个离散选择实验
Hannah Collacott1, Andrea Phillips-Beyer2, Nicolas Krucien3
1Evidera, London, UK. hannah.collacott@evidera.com.
The patient
|January 25, 2024
概括
系统性红斑狼 (SLE) 患者有不同的治疗偏好. 寻求福利的人优先考虑缓解症状,而避免风险的人专注于避免副作用,强调个性化护理需求.
科学领域:
- 类风湿病学 类风湿病学
- 患者报告的结果.
- 卫生经济学 卫生经济学
背景情况:
- 系统性红斑狼 (SLE) 呈现出各种症状,包括关节疼痛,皮疹和疲劳,影响患者的生活质量.
- 现有的SLE治疗方法的疗效各不相同,但往往会带来显著的副作用,尤其是皮质类固醇.
- 关于SLE治疗特征的患者偏好仍然在很大程度上未被探索.
研究的目的:
- 确定影响中度至重度SLE患者治疗选择的关键属性.
- 量化这些属性的在患者决策中的相对重要性.
主要方法:
- 一个在线离散选择实验 (DCE) 涉及成年SLE患者.
- 隐性类型建模 (LCL) 来分析患者在假设治疗之间做出的选择.
- 计算相对属性重要性 (RAI) 来排名治疗因子.
主要成果:
- 确定了两个不同的患者偏好类别:寻求好处的人和避免风险的人.
- 寻求福利的人优先考虑减轻症状 (关节疼痛,非关节疼痛,疲劳,皮疹/).
- 避免风险的人优先考虑避免皮质类固醇的副作用和感染风险,通常与更长的疾病持续时间和之前的皮质类固醇使用有关.
结论:
- 患有SLE的患者的偏好分为侧重于症状 (寻求好处) 和风险 (避免风险) 的两种群体.
- 这些差异可能源于疾病的影响和治疗经验,影响接受治疗风险的意愿.
- 考虑到这些不同的偏好,个性化治疗策略对于有效的SLE管理至关重要.
相关概念视频
Crossover Experiments
2.8K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.8K
Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K


